UPDATE 1-J&J hit with $1.1 bln Risperdal penalty in Arkansas

Wed Apr 11, 2012 2:42pm EDT

* J&J says to appeal award if new trial not allowed

* Arkansas penalty follows $158 mln Texas settlement

* J&J shares little changed

April 11 (Reuters) - An Arkansas state judge has ordered Johnson & Johnson to pay a $1.1 billion penalty after a jury found the company guilty of using fraudulent tactics to sell its Risperdal anti-psychotic medicine.

Arkansas sued the diversified healthcare company, saying it had deceived thousands of doctors in the state by touting the one-time blockbuster medicine as better and safer than rival therapies and marketing it for unapproved uses in children and the elderly.

The state alleged the company had caused its Medicaid insurance program for the poor to greatly overpay for Risperdal.

Following a two-week trial in Pulaski County Circuit Court in Little Rock, a jury on Tuesday found that J&J had marketed the drug inappropriately. Judge Tim Fox handed down the $1.1 billion penalty on Wednesday.

"We are disappointed with the judge's decision on penalties," said J&J spokeswoman Teresa Mueller, who confirmed the award. She said J&J would appeal the award if the company's motion for a new trial is denied.

A clerk for Judge Fox declined to provide details from his decision, saying it had not yet been formally filed with the court.

J&J in January said it would pay $158 million to settle a Texas lawsuit accusing it of improperly marketing Risperdal to patients in that state's Medicaid program, and similar lawsuits are pending in a number of other states. The Texas settlement fully resolved claims in that state but did not affect other state and federal Risperdal litigation.

The U.S. Department of Justice for years has been investigating allegations that J&J marketed Risperdal for unapproved uses, including for nursing home residents. Federal prosecutors in Washington, D.C., earlier this year nixed a tentative $1 billion settlement with J&J, holding out for a bigger settlement with the drugmaker, according to published reports.

J&J shares were off 6 cents at $64.14 in afternoon trade

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see http://blogs.reuters.com/fulldisclosure/2010/09/27/toward-a-more-thoughtful-conversation-on-stories/
Comments (1)
MrJJones99 wrote:
Here’s a good breakdown of the FDA adverse event reporting data on Risperdal:

Apr 13, 2012 11:04am EDT  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.